Krishnaswamy Yeleswaram insider trades: Rapport Therapeutics (RAPP) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Krishnaswamy reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | RAPP | ↓ Sell | 50,160 | $50.47 | $2.5M | Direct | Aug 26, 2026 (1d) |
| Aug 19, 2026 | RAPP | ↓ Sell | 404 | $49.90 | $20K | Direct | Aug 20, 2026 (1d) |
| Apr 14, 2026 | RAPP | ↓ Sell | 19,865 | $35.03 | $696K | Direct | Apr 14, 2026 (0d) |
| Apr 8, 2026 | RAPP | ↓ Sell | 360 | $34.90 | $13K | Direct | Apr 9, 2026 (1d) |
| Dec 31, 2025 | RAPP | ↓ Sell | 2,840 | $30.05 | $85K | Direct | Jan 5, 2026 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RAPP insiders
Open-market trades in the last 12 months
About Krishnaswamy Yeleswaram's insider trades
Krishnaswamy Yeleswaram is Chief Development Officer at Rapport Therapeutics (RAPP). Since Dec 31, 2025, Krishnaswamy has reported no open-market purchases and 5 sales worth $3.3M on SEC Form 4. In the last 12 months: 5 sales ($3.3M).
Their filings also include grants and awards (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RAPP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.